Tilray Sees Cannabis Rescheduling as Gateway to US Medical Market

Tilray Eyes Quick Entry into US Medical Cannabis Market if Federal Reclassification Occurs. Tilray Brands believes it can get into the medical marijuana business in the U.S. pretty quickly if the Biden administration reclassifies cannabis as a Schedule 3 drug sometime this year, CEO Irwin Simon